Barclays PLC Acquires 44,150 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO)

Barclays PLC increased its holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 304.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,655 shares of the medical instruments supplier’s stock after purchasing an additional 44,150 shares during the period. Barclays PLC’s holdings in Harvard Bioscience were worth $157,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of HBIO. State Street Corp lifted its position in shares of Harvard Bioscience by 1.1% in the third quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock worth $1,930,000 after buying an additional 7,763 shares during the last quarter. Harvey Partners LLC increased its holdings in shares of Harvard Bioscience by 6.2% during the 3rd quarter. Harvey Partners LLC now owns 2,715,000 shares of the medical instruments supplier’s stock valued at $7,303,000 after acquiring an additional 157,500 shares during the last quarter. Corsair Capital Management L.P. bought a new position in shares of Harvard Bioscience in the 3rd quarter valued at approximately $63,000. Advantage Alpha Capital Partners LP acquired a new stake in Harvard Bioscience in the 3rd quarter worth approximately $64,000. Finally, Landscape Capital Management L.L.C. bought a new stake in Harvard Bioscience during the third quarter worth approximately $50,000. 80.87% of the stock is owned by institutional investors and hedge funds.

Harvard Bioscience Trading Down 1.8 %

Shares of HBIO stock opened at $2.15 on Wednesday. The business’s 50 day moving average is $2.23 and its two-hundred day moving average is $2.61. The company has a quick ratio of 0.91, a current ratio of 2.06 and a debt-to-equity ratio of 0.52. Harvard Bioscience, Inc. has a 12 month low of $1.95 and a 12 month high of $4.99. The company has a market cap of $93.78 million, a PE ratio of -6.51 and a beta of 1.27.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.